09:20 AM EDT, 05/31/2024 (MT Newswires) -- Novartis AG ( NVS ) said Friday that pivotal phase 3 data showed the long-term efficacy and safety of its investigational drug remibrutinib to treat chronic spontaneous urticaria.

The company said treatment with remibrutinib showed significant symptom improvement that was sustained up to 52 weeks in patients who continued to manifest symptoms despite taking second-generation H1-antihistamine. Remibrutinib also showed a consistent safety profile, including balanced liver function tests, compared with placebo up to 52 weeks, the company added.

Novartis ( NVS ) said it will seek approval for remibrutinib in chronic spontaneous urticaria worldwide starting in H2.

Price: 102.38, Change: +1.68, Percent Change: +1.67